SCHEMBL1383565

SCHEMBL1383565

C#CCn1cc(C(=O)Nc2ccc(S(C)(=O)=O)cc2)c(C)c1-c1ccccc1C(F)(F)F

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 5/20 0.79
FAAH O00519 2/20 0.41
MGLL Q99685 2/20 0.41
PTPRC P08575 1/20 0.39
PDE7A Q13946 2/20 0.39
PDE4A P27815 1/20 0.38
KMT2A Q03164 1/20 0.38
AVPR2 P30518 2/20 0.38
GPR27 Q9NS67 2/20 0.38
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
LMNA P02545 2/20 0.36
MAPT P10636 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CDK1 P06493 1/20 0.36
CDK2 P24941 1/20 0.36
KDR P35968 1/20 0.36
RORC P51449 1/20 0.36
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17646149 0.89 NR3C2 (0.81) NR3C2PTPRCPDE7APDE4AAVPR2
SCHEMBL1381714 0.88 NR3C2 (1.00) NR3C2PTPRCPDE7APDE4AAVPR2
SCHEMBL29571805 0.88 NR3C2 (1.00) NR3C2PTPRCPDE7APDE4AAVPR2
SCHEMBL1381434 0.87 NR3C2 (0.79) NR3C2PTPRCPDE7APDE4AAVPR2
SCHEMBL1381392 0.86 NR3C2 (0.77) NR3C2PTPRCPDE7APDE4AAVPR2
SCHEMBL1379539 0.86 NR3C2 (0.77) NR3C2FAAHMGLLPTPRCPDE7A
SCHEMBL1378883 0.86 NR3C2 (0.90) NR3C2PTPRCPDE7APDE4AAVPR2
SCHEMBL1380002 0.86 NR3C2 (0.88) NR3C2PTPRCPDE7APDE4AAVPR2
SCHEMBL1382075 0.86 NR3C2 (0.76) NR3C2PTPRCPDE7APDE4AAVPR2
SCHEMBL2439584 0.86 NR3C2 (0.79) NR3C2PTPRCAVPR2GPR27MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4703649-B2 2011-06-15 JP claimed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 US disclosed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 US disclosed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 NR3C2 119/4885FAAH 748/4885MGLL 2755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.